Lupin's shares surged by 2.2% following tentative U.S. FDA approval for its generic HIV treatment, Bictegravir, Emtricitabine, and Tenofovi...

Lupin's shares increased by 21.51% over the past year. However, year-to-date (YTD), the stock has decreased by 14.21%. Over the last six mo...

Lupin season 4 will be releasing on Netflix even though the production for the same is yet to commence, according to a report.

Earlier in January, the company received the Establishment Inspection Report (EIR) from USFDA for its Pithampur Unit-1 manufacturing facili...

Indian benchmark indices plummeted almost 3% on Monday amid global market shocks and concerns over a US economy slowdown. RIL, Bharti Airte...

Positive growth in domestic markets for the third consecutive week with a focus on Adani Ports, Cipla, Prestige Estates, MCX, Lupin. Update...

Pharma company Lupin on Monday reported 52% year-on-year growth in its consolidated net profit at Rs 368 crore for the quarter ended March ...

Ace investor Rakesh Jhunjhunwala probably exited this counter in the second quarter, as his name was not among the shareholders holding ove...

‘On a very conservative basis, the drug can add about $300 million to their sales in FY23-FY24.’

The pharma major last week reported a 64.72 per cent decline in its consolidated net profit to Rs 106.90 crore for the quarter to June 2020...

On the NSE, it tumbled 6.24 per cent to Rs 877.80.

Drug firm Lupin has reported a 64.72 per cent decline in its consolidated net profit to Rs 106.90 crore for the quarter to June 2020, hit b...

Clearance in 483 observations indicates increased regulatory compliance by the companies.

"The MSCI India Index is trading at around 22 times earnings, compared to 13.5 times for the MSCI Asia Pacific ex-Japan benchmark."

When the lesser-known names start reacting on the negative side, then there would be a bit of deeper cut, says Shah in an interview with ET...

The stock has gained 25% in the last one year – and has been one of the best performing stocks among the frontline pharma companies.

Lupin Limited, the world's largest maker of drugs to fight tuberculosis, is considering selling its unit that markets drugs in India, said ...